How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

113,706 results for

Treating Family Members

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Dexamethasone intravitreal implant for treating diabetic macular oedema

Dexamethasone intravitreal implant for treating diabetic macular oedema De Dexamethasone intr xamethasone intra avitreal implant for vitreal implant for treating diabetic macular oedema treating diabetic macular oedema T echnology appraisal guidance Published: 22 July 2015 nice.org.uk/guidance/ta349 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) conclusions 49 5 Implementation 58 6 Review of guidance 59 7 Appraisal Committee members, guideline representatives and NICE project team 60 Appraisal Committee members 60 NICE project team 62 8 Sources of evidence considered by the Committee 63 About this guidance 65 Macular oedema (diabetic) - dexamethasone intravitreal implant (TA349) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 661 1 Guidance Guidance 1.1

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

182. Sofosbuvir for treating chronic hepatitis C

Genotype 1 60 Genotype 2 63 Genotype 3 63 Genotypes 4, 5 and 6 68 Summary of Appraisal Committee's key conclusions 76 5 Implementation 88 6 Recommendations for further research 93 7 Review of guidance 94 Sofosbuvir for treating chronic hepatitis C (TA330) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 1038 Appraisal Committee members, guideline representatives and NICE project team 95 Appraisal Committee members (...) Sofosbuvir for treating chronic hepatitis C Sofosbuvir for treating chronic Sofosbuvir for treating chronic hepatitis hepatitis C C T echnology appraisal guidance Published: 25 February 2015 nice.org.uk/guidance/ta330 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view of NICE, arrived at after careful consideration

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

183. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

effectiveness 38 Cost effectiveness 40 Summary of Appraisal Committee's key conclusions 48 5 Implementation 58 6 Review of guidance 59 7 Appraisal Committee members, guideline representatives and NICE project team 60 Appraisal Committee members 60 NICE project team 62 8 Sources of evidence considered by the Committee 63 About this guidance 66 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (TA329) © NICE 2018. All (...) Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy Infliximab, adalimumab and golimumab Infliximab, adalimumab and golimumab for treating moder for treating moderately to se ately to sev verely activ erely active e ulcer ulcerativ ative colitis after the failure of e colitis after the failure of con conv ventional ther entional therap apy y T echnology appraisal guidance Published: 25 February 2015

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

184. Eculizumab for treating atypical haemolytic uraemic syndrome

for further research 37 8 Review of guidance 38 9 Evaluation Committee members and NICE project team 39 Evaluation Committee members 39 NICE project team 40 10 Sources of evidence considered by the Committee 41 About this guidance 44 Eculizumab for treating atypical haemolytic uraemic syndrome (HST1) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 3 of 451 1 Guidance Guidance 1.1 Eculizumab, within its marketing (...) and their families. Often parents of a patient with aHUS, or other family members, have to stop working to be able to provide care. 4.2 Evidence from patient and clinical experts highlighted that patients with aHUS have a greatly impaired quality of life, from both the frequent and severe symptoms they experience and the burden of treatment with dialysis and plasma therapy. Families and carers of patients with aHUS also experience substantial burden, and often have to reduce their work or daily activities

2015 National Institute for Health and Clinical Excellence - Highly specialised technology

185. Omalizumab for previously treated chronic spontaneous urticaria

The company's submission 6 Clinical effectiveness 6 Cost effectiveness 13 Company's additional post-consultation evidence 20 4 Consideration of the evidence 25 Clinical effectiveness 25 Cost effectiveness 30 5 Implementation 45 6 Review of guidance 46 7 Appraisal Committee members, guideline representatives and NICE project team 47 Appraisal Committee members 47 NICE project team 49 8 Sources of evidence considered by the Committee 50 About this guidance 52 Omalizumab for previously treated chronic (...) Omalizumab for previously treated chronic spontaneous urticaria Omalizumab for pre Omalizumab for previously treated viously treated chronic spontaneous urticaria chronic spontaneous urticaria T echnology appraisal guidance Published: 8 June 2015 nice.org.uk/guidance/ta339 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

186. Vedolizumab for treating moderately to severely active ulcerative colitis

Vedolizumab for treating moderately to severely active ulcerative colitis V Vedolizumab for treating moder edolizumab for treating moderately to ately to se sev verely activ erely active ulcer e ulcerativ ative colitis e colitis T echnology appraisal guidance Published: 5 June 2015 nice.org.uk/guidance/ta342 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Vedolizumab for treating moderately to severely active ulcerative colitis (TA342) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 51Contents Contents 1 Guidance 4

2015 National Institute for Health and Clinical Excellence - Technology Appraisals

187. Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. Full Text available with Trip Pro

Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. Keratinocytes can function as innate immune cells under oxidative stress and aggravate the cutaneous T-cell response that undermines melanocytes in the setting of vitiligo. The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is a regulator of innate immunity that exists in keratinocytes. However, the role of the NLRP3 (...) inflammasome in the pathogenesis of vitiligo has not been investigated.We sought to explicate the contribution of the activated NLRP3 inflammasome in keratinocytes to the autoimmune response in patients with vitiligo.Perilesional and serum samples from patients with vitiligo were collected to examine the status of the NLRP3 inflammasome in the setting of vitiligo. Cultured keratinocytes were treated with H2O2 to investigate the mechanism for NLRP3 inflammasome activation under oxidative stress. Peripheral

2020 Journal of Allergy and Clinical Immunology

188. Risk of pelvic organ prolapse treatment based on extended family history. (Abstract)

of treated (surgical or pessary) pelvic organ prolapse and their 15,530 first-degree relatives; 33,782 second-degree relatives, and 66,469 third-degree relatives. We estimated relative risk of treated pelvic organ prolapse based on specific family history constellations.Relative risk estimates increased with a family history of increasing numbers of treated first-degree relatives with pelvic organ prolapse (first-degree relatives, ≥1 [relative risk, 2.36; 95% confidence interval, 2.15-2.58], first-degree (...) relatives, ≥2 [relative risk, 3.79; 95% confidence interval, 2.65-5.24], and first-degree relatives, ≥3 [relative risk, 6.26; 95% confidence interval, 1.29-18.30]). Having a family history of ≥3 affected third-degree relatives (eg, first cousins) and no affected first- or second-degree relatives was similar in risk to having 1 affected first-degree relative. Relative risk estimates decreased with increasing age of treatment for first-degree family members. Risks in individuals with a positive maternal

2020 American Journal of Obstetrics and Gynecology

189. Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields

with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Sampling Method: Non-Probability Sample Study Population Patients diagnosed with WHO Grade IV malignant glioma who are approved for and intend (...) Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2018 Clinical Trials

190. Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Patients (...) Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2018 Clinical Trials

191. Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant

survival [ Time Frame: Up to 1 year ] Unadjusted distributions of time-to-event outcomes will be estimated using the method of Kaplan and Meier and their relationship to prognostic covariates and veto cell dose level will be evaluated by Bayesian piecewise exponential survival regression. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding (...) Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

192. Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

between baseline AR-V7 status and PFS as well as OS and its interaction with treatment. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility (...) Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2018 Clinical Trials

193. Attitudinal concordance toward uptake and disclosure of genetic testing for cancer susceptibility in patient-family member dyads. (Abstract)

a reliable CSGT was available for the specific cancer a patient was being treated. While most patients and family members responded they would uptake or recommend CSGT if available, concordance between the dyads was poor for both patient's testing (agreement rate 77.5%, weighted κ=0.09) and first-degree relatives' testing(agreement rate 78.0%, weighted κ=0.09). Most patients (93.2%) and family members (92.9%) indicated that patients should disclose positive CSGT results to family members, with dyadic (...) Attitudinal concordance toward uptake and disclosure of genetic testing for cancer susceptibility in patient-family member dyads. Decisions for cancer susceptibility genetic testing (CSGT) uptake and dissemination of results occur within the family context. A national survey was performed with 990 patient-family member dyads (participation rate:76.2%), with paired questionnaires examining attitudes toward CSGT uptake and disclosure of results in response to a hypothetical scenario in which

2014 Clinical Genetics

194. Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. Full Text available with Trip Pro

Deep Sequencing the microRNA profile in rhabdomyosarcoma reveals down-regulation of miR-378 family members. Rhabdomyosarcoma (RMS) is a highly malignant tumour accounting for nearly half of soft tissue sarcomas in children. MicroRNAs (miRNAs) represent a class of short, non-coding, regulatory RNAs which play a critical role in different cellular processes. Altered miRNA levels have been reported in human cancers, including RMS.Using deep sequencing technology, a total of 685 miRNAs were (...) -378 family members were dramatically decreased in RMS tumour tissue and cell lines. Interestingly, members of the miR-378 family presented as a possible target the insulin-like growth factor receptor 1 (IGF1R), a key signalling molecule in RMS. MiR-378a-3p over-expression in an RMS-derived cell line suppressed IGF1R expression and affected phosphorylated-Akt protein levels. Ectopic expression of miR-378a-3p caused significant changes in apoptosis, cell migration, cytoskeleton organization as well

2014 BMC Cancer

195. How do family physicians measure blood pressure in routine clinical practice?: National survey of Canadian family physicians Full Text available with Trip Pro

How do family physicians measure blood pressure in routine clinical practice?: National survey of Canadian family physicians To describe the techniques currently used by family physicians in Canada to measure blood pressure (BP) for screening for, diagnosing, and treating hypertension.A Web-based cross-sectional survey distributed by e-mail.Stratified random sample of family physicians in Canada.Family physician members of the College of Family Physicians of Canada with valid e-mail (...) (63.6%, 489 of 769) and AOBP measurement (59.2%, 455 of 769). More than three-quarters (77.8%, 598 of 769) of respondents indicated that ABPM was readily available for their patients.Canadian family physicians exhibit overall high use of electronic devices for BP measurement, However, more efforts are needed to encourage practitioners to follow current Canadian guidelines, which advocate the use of AOBP measurement for hypertension screening, ABPM and home BP measurement for making a diagnosis

2017 Canadian Family Physician

196. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2

, Poppe B. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 243. 2015 Authors' objectives This guideline treats the Birt-Hogg-Dubé syndrome, the familial atypical multiple mole melanoma syndrome and neurofibromatosis 1&2. These syndromes only have in common that dermatological manifestations are involved, but implications, risks (...) Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2 Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Oncogenetic testing, diagnosis and follow-up in Birt-Hogg-Dubé syndrome, familial atypical multiple mole melanoma syndrome and neurofibromatosis 1 and 2. Robays J, Stordeur S, Hulstaert F

2015 Health Technology Assessment (HTA) Database.

197. Familial Hypercholesterolaemia

in a member of an affected family is suggestive of FH, particularly in the case of younger relatives. Other affected individuals can usually be identified on the basis of LDL-C levels, but studies suggest that a misdiagnosis rate of approximately 15% may apply. Several sets of diagnostic criteria have been developed, including: a) Dutch Lipid Clinic criteria: 8 points DNA Mutation, or LDL-C > 8.5 6 points Tendon xanthomas 5 points LDL-C 6.5 – 8.4 4 points Arcus senilis 95 th percentile, or premature CHD 1 (...) management of FH (6). Although the clinical picture of FH will be clear-cut in many instances, the diagnostic criteria suggest that genetic testing can provide certainty of diagnosis in some cases where confounding factors such as borderline cholesterol levels, inconclusive family histories or tendon injuries have resulted in a diagnostic dilemma. The major value in making a molecular diagnosis is its use in predictive testing of other family members for FH. This is useful in early detection of cases

2016 Cardiac Society of Australia and New Zealand

198. A transient DMSO treatment increases the differentiation potential of human pluripotent stem cells through the Rb family. Full Text available with Trip Pro

, we demonstrated that pre-treating hPSCs with dimethylsulfoxide (DMSO) before directed differentiation enhanced differentiation potential across all three germ layers. Here, we show that exposure to DMSO improves the efficiency of hPSC differentiation through Rb and by repressing downstream E2F-target genes. While transient inactivation of the Rb family members (including Rb, p107, and p130) suppresses DMSO's capacity to enhance differentiation across all germ layers, transient expression (...) A transient DMSO treatment increases the differentiation potential of human pluripotent stem cells through the Rb family. The propensity for differentiation varies substantially across human pluripotent stem cell (hPSC) lines, greatly restricting the use of hPSCs for cell replacement therapy or disease modeling. Here, we investigate the underlying mechanisms and demonstrate that activation of the retinoblastoma (Rb) pathway in a transient manner is important for differentiation. In prior work

2018 PLoS ONE

199. A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. Full Text available with Trip Pro

A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. Familial adenomatous polyposis (FAP) is an inherited condition arising from genetic defects in the Adenomatous polyposis coli (APC) gene. Carriers with mutations in the APC gene develop polyps in the colon and rectum which if not managed, transition into colon cancer. In this study, we identified a novel germline mutation in the APC gene in members of an FAP (...) -affected (Familial adenomatous polyposis) family. This unique heterozygous variant (c.735_736insT; p.Ser246PhefsTer6) was identified in ten out of twenty six family members, ranging in age from 6 to 60 years. Polyps were detected in six of the ten individuals (35-60 years) carrying this mutation. The remaining four members (6-23 years) remain polyp free. A significant fraction of FAP affected individuals eventually develop colon cancer and therapeutic interventions to prevent cancer progression remain

2018 PLoS ONE

200. Family Building Through Gestational Surrogacy

of information discovered in the course of treatment should be included in the written preconception agreement to provide guidance to the treating physician. Such written agreements are equally important in arrangements that involve gestational carriers who are friends or family members of the intended parent(s) ( ) . Psychosocial Considerations The psychosocial effects of gestational surrogacy on the resulting offspring as well as on the gestational surrogate and her family are important considerations (...) Family Building Through Gestational Surrogacy Family Building Through Gestational Surrogacy - ACOG Menu ▼ Family Building Through Gestational Surrogacy Page Navigation ▼ Number 660, March 2016 (Replaces Committee Opinion No. 397, February 2008) Committee on Ethics This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Ethics. Member contributors included Ginny L. Ryan, MD. While this document reflects the current viewpoint of the College

2016 American College of Obstetricians and Gynecologists

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>